These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19355860)

  • 1. Potential options to treat hypertriglyceridaemia.
    Viljoen A; Wierzbicki AS
    Curr Drug Targets; 2009 Apr; 10(4):356-62. PubMed ID: 19355860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hypertriglyceridemia: a review of current options.
    Vrablík M; Češka R
    Physiol Res; 2015; 64(Suppl 3):S331-40. PubMed ID: 26680666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demystifying the management of hypertriglyceridaemia.
    Watts GF; Ooi EM; Chan DC
    Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for severe hypertriglyceridemia treatment, are there new strategies?
    Filippatos TD; Elisaf MS
    Curr Vasc Pharmacol; 2014; 12(4):598-616. PubMed ID: 23627980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.
    Hallén J; Sreeharan N
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):237-242. PubMed ID: 30060063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review.
    Kolovou GD; Watts GF; Mikhailidis DP; Pérez-Martínez P; Mora S; Bilianou H; Panotopoulos G; Katsiki N; Ooi TC; Lopez-Miranda J; Tybjærg-Hansen A; Tentolouris N; Nordestgaard BG
    Curr Vasc Pharmacol; 2019; 17(5):515-537. PubMed ID: 31309820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis.
    He W; Lu N
    Hepatogastroenterology; 2015; 62(138):429-34. PubMed ID: 25916076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation and management of hypertriglyceridaemia.
    Ferns G; Keti V; Griffin B
    J Clin Pathol; 2008 Nov; 61(11):1174-83. PubMed ID: 18955574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridaemia and risk of coronary artery disease.
    Reiner Ž
    Nat Rev Cardiol; 2017 Jul; 14(7):401-411. PubMed ID: 28300080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Beginning for Triglyceride-Lowering Therapies.
    Pradhan AD
    Circulation; 2019 Jul; 140(3):167-169. PubMed ID: 30836784
    [No Abstract]   [Full Text] [Related]  

  • 18. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
    Maki KC; Guyton JR; Orringer CE; Hamilton-Craig I; Alexander DD; Davidson MH
    J Clin Lipidol; 2016; 10(4):905-914. PubMed ID: 27578122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.
    Tenenbaum A; Klempfner R; Fisman EZ
    Cardiovasc Diabetol; 2014 Dec; 13():159. PubMed ID: 25471221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.
    Brinton EA
    Cardiol Clin; 2015 May; 33(2):309-23. PubMed ID: 25939302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.